NCT02753946 - Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections | Biotech Hunter

Enrollment

465

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 12, 2017

Study Completion Date

May 30, 2017

Conditions

Urinary Tract Infection SymptomaticAcute PyelonephritisUrinary Tract Infection Complicated

Interventions

DRUG

ZTI-01

6g ZTI-01 intravenous infusion TID q8 hours

DRUG

Piperacillin-tazobactam

4.5g piperacillin-tazobactam intravenous infusion TID q8 hours

Trial Locations (68)

Unknown

Pensacola

Augusta

Columbus

Boylston

St Louis

Butte

Brest

Grodno

Homyel

Minsk

Vitebsk

Plovdiv

Sofia

Slavonski Brod

Split

Zagreb

Brno

Hradec Králové

Liberec

Kohtla-Järve

Tallinn

Batumi

Kutaisi

Tbilisi

Ampelokipoi

Athens

Thessaloniki

Budapest

Miskolc

Nagykanizsa

Pécs

Szekszárd

Szentes

Riga

Valmiera

Kaunas

Klaipėda

Vilnius

Bielsko-Biala

Krakow

Lodz

Piaseczno

Tychy

Wroclaw

Zamość

Bucharest

Craiova

Oradea

Krasnoyarsk

Moscow

Moscow, Zelenograd

Nizhny Novgorod

Novosibirsk

Penza

Rostov-on-Don

Saint Petersburg

Saratov

Smolensk

Vsevolozhsk

Martin

Poprad

Žilina

Chernihiv

Dnipropetrovsk

Kharkiv

Kyiv

Odesa

Zaporizhzhia